Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
The European Medicines Agency confirms that Intervacc’s application for the granting of a Community marketing authorization for Strangvac is complete and correctly submitted
Stockholm March 18, 2020 – Intervacc AB (publ) announces that the European Medicines Agency, EMA, has today confirmed that the company’s application for the granting of a Community marketing authorization for Strangvac is complete and correctly submitted....Intervacc announces submission of the Marketing Authorization Application for Strangvac to the European Medicines Agency
Stockholm February 26, 2020 – Intervacc AB (publ) announces that the Company’s Marketing Authorization Application (MAA) for review of Strangvac® has been submitted today to the European Medicines Agency (EMA). Intervacc is seeking approval for Strangvac® as a...Intervacc appoints new CFO and new VP supply chain management
Intervacc is pleased to announce the appointment of Jan Persson as the new CFO for the Intervacc Group as well as a member of the group management team. Jan Persson succeeds Andreas Johansson, who will become VP supply chain management. Andreas Johansson, who will be...Validation batches of Strangvac completed
Intervacc has, together with 3P Biopharmaceuticals and LIOF-Pharma (previously Praxis Pharmaceuticals), completed the manufacturing process for Strangvac®. The validation production batches required for the forthcoming registration application to the European...Updated timetable for submission of the application to the European Medicines Agency
Intervacc will shortly apply to the European Medicines Agency (EMA) to submit the company’s registration application for Strangvac’s approval during the first quarter of 2020. The company has today decided to enter into a dialogue with EMA about submitting...Nyhetstjänster
